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Toxoplasma gondii Serostatus Is Not Associated
With Impaired Long-Term Survival after
Heart Transplantation
Jaap J. van Hellemond,1 Ron T. van Domburg,2,3 Kadir Caliskan,2 Ozcan Birim,3 and Aggie H. Balk2,4
Background. Conflicting data have been reported about the effect of Toxoplasma serostatus on mortality after heart
transplantation. Either a positive or a negative recipient Toxoplasma serostatus was found to be associated with in-
creased mortality.
Methods. We evaluated the effects of T. gondii infection on survival of our 582 cardiac allograft recipients operated
upon between June 1984 and July 2011.
Results. The 258 Toxoplasma seronegative and 324 seropositive recipients differed in age, pretransplantation diag-
nosis, ischemia time, renal function, donor Toxoplasma serology, and maintenance immunosuppression. After a
median follow-up time of 8.3 years (range, 0Y26 years), 117 (45%) seronegative and 219 (67%) seropositive patients
died. No difference was found in deaths due to cardiac allograft vasculopathy. After adjustment for all relevant clinical
characteristics, the recipient Toxoplasma serostatus was not associated with mortality (hazard ratio, 1.21; 95% con-
fidence interval [CI], 0.95Y1.54). With the Toxoplasma serostatus combination donor negative/recipient negative as a
reference, univariate hazard ratios for the Toxoplasma serostatus combinations were D+/R- 0.52 (95% CI, 0.37Y0.73),
D-/R+ 0.65 (95% CI, 0.40Y1.05), and D+/R+ 0.78 (95% CI, 0.57Y1.07). Multivariate analysis, however, showed that
donor Toxoplasma serostatus was not independently associated with mortality.
Conclusions. The Toxoplasma serostatus of both the recipient and donor appeared not to be independent risk factors
for mortality after heart transplantation.
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Until now, two studies investigated whether the long-term survival after heart transplantation is affected by
the Toxoplasma serostatus of the recipient and the donor
(1, 2). These studies, however, yielded conflicting results as
to the recipient serostatus. Arora et al. reported that a
Toxoplasma seropositive status in heart transplant recipients
was associated with an increased risk of all-cause mortality
as well as risk of death by cardiac allograft vasculopathy and
Doesch et al. reported that a Toxoplasma seronegative status
was associated with an increased mortality risk (1, 2). In
both studies, no association of donor serostatus and mor-
tality was found.
Toxoplasma gondii is an obligate intracellular protozoan
parasite with a worldwide distribution that can invade and
replicate in almost all nucleated cells of warm-blooded mam-
mals. After the primary acute infection, the parasite remains in
the body in a quiescent state by the formation of tissue cysts
in predominantly muscle and brain tissue. Therefore, toxo-
plasmosis is a lifelong infection and the prevalence of human
T. gondii infections thus increases with age. Its prevalence is
reported to be more than 50% in many parts of the world (3).
In immunocompetent individuals, the infection is usually
asymptomatic, although cases of severe disease due to unusual
T. gondii genotypes from South and Central America have
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been reported (4). In immunocompromised patients, how-
ever, toxoplasmosis can be a severe disease (3).
Solid-organ transplant recipients are immunocom-
promised due to the required high dose of immunosuppres-
sive medication. Heart transplant recipients are known to be
at risk for toxoplasmosis, especially when recipients are se-
ronegative (and thus naBve for T. gondii) and receive a heart
transplant, containing tissue cysts, from a T. gondiiYinfected
donor (5). In these cases, prophylactic treatment is indicated to
prevent toxoplasmic myocarditis and fatal disseminated toxo-
plasmosis (5, 6). Also, antibiotic drugs, administered prophy-
lactically to Toxoplasma mismatched recipients, could have a
direct or indirect immunomodulatory effect and could nega-
tively influence patient outcome by their side effects (7).
Cardiac allograft vasculopathy, a process in which
chronic inflammation and immune activation play an im-
portant role, is a major cause of death after heart trans-
plantation (8, 9). A T. gondii infection might influence the
host immunologic status and thereby affect the risk for
cardiac allograft vasculopathy. Therefore, the effects of a
T. gondii infection on the survival after heart transplantation
have been subject of study. Because of the earlier conflicting
results of studies, which involved rather small numbers of
patients and a limited follow-up duration, we performed a
study on our whole population of heart transplant recipients
to evaluate the effects of a T. gondii infection in the recipient
and/or the donor on survival after heart transplantation.
RESULTS
Between June 1984 and July 2011, a total of 582 heart
transplants have been performed in 577 patients. Recipients
with a retransplant have been assessed as separate cases.
Follow-up was complete in all cases. The Toxoplasma sero-
status of the 582 cases was determined and Table 1 shows
the characteristics of cardiac allograft recipients accord-
ing to their pretransplantation Toxoplasma serostatus. The
324 Toxoplasma seropositive cases were 10 years older than
the 258 seronegative cases, suffered more often from ische-
mic heart disease, and had worse renal function. Due to
missing serum samples, the serostatus of 155 donors was
unknown. One hundred five (41%) of the Toxoplasma
TABLE 1. Characteristics of all 582 cardiac
allograft recipients
Toxoplasma
serostatus
PNegative Positive
Number of patients, n (%) 258 (44) 324 (56)
Recipient
Female gender, n (%) 81 (31) 61 (19) 0.0001
Age (years; meanTSD) 41T16 51T10 G0.0001
G19, n (%) 37 (14) 5 (1.5) G0.0001
19Y59, n (%) 204 (79) 268 (83) 0.26
959, n (%) 17 (7) 51 (16) 0.0006
Pretransplantation diagnosis
Cardiomyopathy, n (%) 142 (55) 131(40) 0.0006
Ischemic heart disease 103 (40) 179 (55) 0.0002
Failure of first graft 2 3 NS
Other 11 (4) 11 (3) NS
Prior cardiac surgery 67 (26) 77 (24) 0.30
PRA 90 (number of patients) 76 (31) 99 (32) 0.87
Long-term LVAD 9 (3) 5 (2) NS
CMV seronegative 121 (47) 140 (43) 0.39
CMV mismatch (D+/R-) 58 (22) 69 (21) 0.76
Serum creatinine pre-Tx
(L; Hmol/L meanTSD)
110T42 125T52 G0.0001
Diabetes mellitus pre-Tx, n (%) 17 (6) 16 (5) 0.30
Donor
Female gender, n (%) 129 (51) 144 (44) 0.17
Age (years; meanTSD) 32T14 33T13 0.48
G51, n (%) 230 (91) 282 (88) 0.46
950, n (%) 24 (9) 37 (12) 0.42
Cause of death, n (%)
Trauma 94 (41) 138 (48) 0.11
Hemorrhagic stroke 116 (51) 139 (48) 0.63
MM AB+DR 94, n (%) of patients 121 (48) 167 (52) 0.26
Toxoplasma seropositive, n (%) 105 (41) 85 (26) 0.003
Toxoplasma serostatus unknown 29 (11) 126 (38) G0.0001
Operation
Ischemia time (min; meanTSD) 180T44 171T43 0.02
Postoperative course
Induction therapy, n (%) 202 (78) 244 (76) 0.52
Maintenance immunosuppression,
n (%)
Cyclosporine based 117 (48) 203 (68) G0.0001
Tacrolimus based 133 (52) 99 (32) G0.0001
+MMF 64 (26) 54 (18) 0.02
Statin started immediately post-Tx 123 (48) 123 (38) 0.05
Acute rejection
0 episodes, n (%) of patients 58 (22) 79 (25) 0.59
92 episodes, n (%) of patients 55 (21) 82 (25) 0.26
CMV disease, n (%) 33 (14) 60 (20) 0.06
Treatment for hypertension at
1 year
160 (62) 228 (70) 0.09
Diabetes mellitus post-TX 59 (23) 80 (25) 0.84
TABLE 1. (Continued)
Toxoplasma
serostatus
PNegative Positive
Serum creatinine at 1 year
(Hmol/L; meanTSD)
127T66 145T67 0.003
Cholesterol at 1 year
(mmol/L; meanTSD)
6.4T5.5 6.4T2.3 0.82
Triglycerides at 1 year
(mmol/L, meanTSD)
3.6T1.4 2.3T1.2 0.12
CAV at 1 year n (%) of resp.
230/280 CAG
19 (8) 26 (9) 0.75
CAV at 4 years n (%) of resp.
171/218 CAG
25 (15) 36 (17) 0.78
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seronegative recipients and 85 (26%) of the Toxoplasma sero-
positive recipients received the heart of a seropositive donor.
The use of induction immunosuppression was not
different between Toxoplasma seropositive and seronegative
cases, but the Toxoplasma seropositive recipients received
more often cyclosporine instead of tacrolimus for main-
tenance immunosuppression (Table 1). Early statins were
more often administered to Toxoplasma seronegative pa-
tients. During follow-up, there were no differences in the
number of rejection episodes, in the occurrence of cyto-
megalovirus (CMV) disease, or in treatment of hypertension
and diabetes mellitus. The prevalence of cardiac allograft
vasculopathy, shown at routine angiography after 1 and
4 years, was similar in both groups.
Mortality and T. gondii Seropositivity
During a median follow-up time of 8.3 years (range,
0Y26 years) 336 transplant recipients died, of whom 219 (65%)
were Toxoplasma seropositive and 117 (35%) were Toxoplasma
seronegative. Long-term cumulative survival of the (unad-
justed) Toxoplasma seropositive patients appeared worse
than that of the Toxoplasma seronegative patients (Fig. 1).
Causes of death were comparable between the Toxoplasma
seropositive and seronegative recipients (Table 2). Espe-
cially, no difference was found in deaths due to cardiac allo-
graft vasculopathy defined as late cardiac death. (Table 2).
This applied to all recipients as well as to the 4-year survivors.
Univariate analysis of all-cause mortality in all 582
cases showed that, besides recipient Toxoplasma seroposi-
tivity, recipient age, ischemic heart disease, pretransplanta-
tion diabetes mellitus, reoperation, pretransplantation and
1-year posttransplantation renal function, and cardiac allo-
graft vasculopathy at 1 and 4 years were risk factors of mor-
tality, whereas tacrolimus (instead of cyclosporine)Ybased
immunosuppression and early statins appeared to be pro-
tective (Table 3). After adjustment for all relevant clinical
characteristics independent of the P value, as described in
Table 3, the recipient Toxoplasma serostatus was not associ-
ated with higher mortality (hazard ratio [HR], 1.21; 95%
confidence interval [CI], 0.95Y1.54; P=0.18).
Multivariate analysis of the Toxoplasma serostatus com-
binations shown in Table 3 showed that donor Toxoplasma
serostatus was not independently associated with mor-
tality (HR [95% CI], D+/R- 0.74 [0.52Y1.06], D-/R+ 0.88
[0.53Y1.46], and D+/R+ 0.82 [0.56Y1.20]). Analysis of the
510 one-year survivors showed that female gender of the
recipient was an extra univariate risk factor of mortality (not
shown). Multivariate analysis confirmed characteristics as
recipient age and cyclosporine-based immunosuppression
(vs. tacrolimus) as independent risk factors of mortality and
the protective effect of early statins (Table 4). Pretrans-
plantation diabetes mellitus was an independent risk factor
in all patients and in the 1-year survivors.
DISCUSSION
We showed that the long-term survival of heart
transplant recipients is not associated with the Toxoplasma
FIGURE 1. Survival of all recipients according to Toxoplasma serostatus.
TABLE 2. Causes of death in all patients
Recipient Toxoplasma serostatus
Negative Positive P
Patients 258 324
Deaths, n (%) 117 (45) 219 (67) G0.0001
Cause of death
Early cardiac 11 (9) 22 (10) 1.00
Acute rejection 8 (7) 9 (4) 0.30
Infection 10 (9) 19 (9) 1.00
Malignancy 20 (17) 40 (18) 0.88
Vascular disease 9 (8) 28 (13) 0.20
Late cardiac 33 (28) 53 (24) 0.43
Other 26 (22) 48 (22) 1.00
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serostatus of neither the recipient nor the donor. By inclu-
sion of more patients and a longer follow-up period, our
results may partly solve the disagreement between earlier
findings (1, 2).
Beneficial effects of the early use of statins and
tacrolimus-based maintenance immunosuppression have been
reported earlier from the U.S. and European centers (10Y13).
Therefore, an imbalance of beneficial demographics in our
Toxoplasma seronegative recipients (younger, less ischemic
heart disease, better renal function, more tacrolimus main-
tenance immunosuppression, and more early statin use)
may have masked a true mortality risk. We assume, however,
that this has been overcome by putting all known risk fac-
tors into the multivariate model.
Searching for an explanation of the contradictory re-
sults of the studies of Arora et al. (1) and Doesch et al. (2)
and our study, we demonstrated several differences between
the studies. A summary is presented in Table 5. Populations
differ not only in patient demographics but also in per-
centages of Toxoplasma seronegative recipients and in per-
centages of donors with unknown Toxoplasma serostatus.
No Toxoplasma prophylactic treatment was used in the
study of Arora et al. (1). The most obvious difference,
however, is the time period covered by the studies. Time as
a confounding factor applies above all to our study, which
includes almost the whole history of calcineurin inhibitorY
based heart transplantation. Multivariate analysis of all
known risk factors will not completely have corrected for
this issue. We refrained from adding ‘‘era’’ effect as a risk
factor in to the analysis because of too much overlap of
the different eras at different time points in diagnostic
procedures (for CMV, toxoplasmosis, acute rejection, and
cardiac allograft vasculopathy) as well as in therapeutic
strategies (CMV prophylaxis, Toxoplasma prophylaxis, in-
duction and maintenance immunosuppression, use of statins,
etc.). When we included ‘‘year of transplant’’ as a continu-
ous variable the HR (95% CI) was 0.80 (0.79Y0.82) but in
the multivariate model, there was large confounding with
several other variables such as ‘‘early statin,’’ which was given
only after 1995. Therefore, we had to remove ‘‘year of
transplant’’’ from the model.
Others demonstrated an association of recipient
Toxoplasma seropositivity with especially mortality due to
cardiac allograft vasculopathy (1). The background of such
TABLE 3. Univariate predictors of all-cause mortality in
all patients
HR 95% CI P
Recipient
Female gender 1.174 0.897Y1.538 0.24
Age 1.027 1.017Y1.037a G0.001
Ischemic heart disease 1.528 1.230Y1.899a G0.001
PRA 9 0 1.184 0.948Y1.480 0.147
CMV seropositive 1.174 0.946Y1.459 0.15
CMV mismatch (D+/R-) 0.833 0.635Y1.094 0.19
Toxoplasma seropositive 1.496 1.193Y1.875a G0.001
Serum creatinine pre-Tx 1.002 1.000Y1.004a 0.03
Diabetes mellitus pre-Tx 1.216 1.024Y1.444a 0.03
Donor
Female gender 1.001 0.806Y1.245 0.99
Age 1.006 0.996Y1.015 0.25
Trauma cause of death 1.078 0.851Y1.364 0.53
MM AB+DR 9 4 1.025 0.827Y1.270 0.82
Donor/recipient Toxoplasma
serostatus combinations
Donor/recipient negative/negative
(reference)
1.00
Donor/recipient positive/negative 0.524 0.037Y0.73 G0.001
Donor/recipient negative/positive 0.65 0.40Y1.05 0.08
Donor/recipient positive/positive 0.78 0.57Y1.07 0.12
Operation
Reoperation 1.224 1.022Y1.466a 0.03
Ischemia time 1.000 0.998Y1.003 0.75
Postoperative course
Induction therapy 0.942 0.757Y1.173 0.59
Maintenance immunosuppression
Cyclosporine based 2.830 2.111Y3.794a G0.001
Tacrolimus based 0.353 0.264Y0.474a G0.001
Early statin per protocol 0.485 0.367Y0.640a G0.001
Acute rejection
Number of episodes 0 0.805 0.623Y1.041 0.10
Number of episodes 92 0.881 0.652Y1.191 0.41
CMV disease 0.989 0.738Y1.326 0.94
Treated hypertension at 1 year
post-Tx
0.672 0.530Y0.852a 0.001
Diabetes mellitus post-Tx 0.986 0.791Y1.228 0.90
Serum creatinine at 1 year post-Tx 1.003 1.001Y1.004a G0.001
Total cholesterol at 1 year post-Tx 0.937 0.884Y0.994a 0.03
Triglycerides at 1 year post-Tx 0.923 0.838Y1.077 0.115
CAV at 1 year post-Tx 1.097 1.026Y1.173a 0.01
CAV at 4 years post-Tx 1.116 1.043Y1.194a 0.002
a Significant difference.
TABLE 4. Multivariate predictors of all-cause mortality
HR 95% CI P
All patients
Recipient age 1.028 1.011Y1.046 0.001
Diabetes mellitus pretransplantation 2.267 1.027Y5.004 0.04
Cyclosporine-based maintenance
immunosuppression
2.564 1.611Y4.080 G0.001
Early statin per protocol 0.518 0.305Y0.879 0.02
1-year survivors
Recipient age 1.029 1.012Y1.047 0.001
Diabetes mellitus pretransplantation 2.344 1.061Y5.179 0.035
Cyclosporine-based maintenance
immunosuppression
2.655 1.656Y4.255 G0.001
Early statin per protocol 0.488 0.283Y0.839 G0.001
4-year survivors
Recipient age 1.037 1.011Y1.063 0.005
Cyclosporine-based maintenance
immunosuppression
2.251 1.289Y3.930 0.004
Early statin per protocol 0.319 0.143Y0.712 G0.001
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association is based on the fact that cardiac allograft
vasculopathy is a process in which chronic inflammation
and immune activation play an important role (8, 9). Upon
infection by T. gondii, the host immune system is ma-
nipulated by parasite secreted factors that induce a pro-
inflammatory response resulting in the production of
interleukin-12 by monocytes, neutrophils, and dendritic
cells and interferon-F by natural killer cells and T-cells (14).
Subsequently, a delicate balance between proinflammatory
and anti-inflammatory signals is required to convert the
active primary infection to its chronic and latent phase
that allows both host and parasite survival (15). For these
reasons, the immunologic effects of a T. gondii infection
might influence the risk for cardiac allograft vasculopathy.
However, we could not confirm the association of re-
cipient Toxoplasma seropositivity and the occurrence of
cardiac death.
The antibiotic prophylactic drugs given to Toxoplasma
mismatch recipients (D+/R-) could also have a direct or
indirect immunomodulatory effect. Although such a phe-
nomenon has not been reported for pyrimethamine and
sulfadiazine, spiramycin induces increased interleukin-6
production by monocytes in vitro (7). In addition, patient
outcome could be negatively influenced by side effects of
the antibiotic prophylactic drugs. Spiramycine is hepato-
toxic, pyrimethamine can induce bone marrow suppression,
and sulfadiazine is hepatotoxic and nephrotoxic. However,
oral folinic acid administration prevents the negative side
effects of a pyrimethamine-sulfadiazine regimen in most
cases. This study, as well as the studies by Arora et al. (1) and
Doesch et al. (2), did not identify a difference in mortality
between Toxoplasma seronegative recipients that received
the heart of a seropositive versus a seronegative donor,
suggesting that the antibiotic prophylactic drugs given to
Toxoplasma mismatch recipients (D+/R-) do not negatively
affect outcome.
Our analyses confirmed recipient age and pretrans-
plantation diabetes mellitus as independent risk factors for
mortality. Our finding that cyclosporine (vs. tacrolimus) for
maintenance imunosuppression appeared to be an inde-
pendent risk factor of all-cause mortality confirms the re-
sults of Guethoff et al., who recently showed a survival
benefit of tacrolimus versus cyclosporine in the 10-year
follow-up of a randomized trial (12). Early prescription of
statins had a protective effect as has been demonstrated by
others in short-term as well as in long-term studies (10, 11).
In conclusion, we found that neither the Toxoplasma
serostatus of the transplant recipient nor the serostatus of
the donor is an independent risk factor for mortality after
heart transplantation. Time bias, however, may have acted as
a confounding factor for our results, but long term studies
in a field with frequent changes in diagnostic and thera-
peutic strategies will always be harmed by the effects of time.
Limitations of the Study
Our analysis involved all heart transplant recipients,
from the start of the program in 1984. This resulted in a
study population that embraced the whole evolution of
heart transplantation with increasing recipient and do-
nor ages, different diagnostic laboratory methods, different
immunosuppression protocols, and different therapies for
infection prophylaxis. In addition, statins early after trans-
plantation were introduced only from 2000. Another lim-
itation is the lack of donor Toxoplasma serostatus in a
considerable number of transplant recipients. The larger
percentage of unknown donor Toxoplasma serostatus in the
seropositive recipients can be explained by the fact that
more effort was put in finding out the donor serostatus in
seronegative recipients because of the required prophylaxis
in case of a mismatch. In this respect, however, it may be
important that Toxoplasma seronegative recipients of a do-
nor with unknown serostatus have received the, for that
time, usual prophylactic treatment.
MATERIALS AND METHODS
Patients
From the start of the heart transplant program in 1984, clinical data of
all heart transplant recipients have been prospectively collected. Patients
consented to use deidentified data for research purposes and the institu-
tional review board of the Erasmus MC approved the present study. En-
rolled were all cases who underwent heart transplantation between June
1984 and July 2011. For the study, the database was closed on July 15, 2012.
Patients with preformed donor-specific antiYhuman leukocyte antigen
antibodies (panel-reactive antibody [PRA]94%) were only transplanted
after a negative crossmatch. During the early years of the program, only
donors under age 36 were accepted for transplantation. Later on, the upper
TABLE 5. Comparison between studies on Toxoplasma
serostatus and survival after heart transplantation
Arora
et al. (1)
Doesch
et al. (2)
Current
study
Number of patients 288 344 582
Recipient age (years, mean) 54 52 47
Donor age (years, mean) 36 38 32
Toxoplasma seronegative
recipients (%)
73 55 44
Unknown donor Toxoplasma
serology (%)
15 ? 27
CMV mismatch D+/R- (%) 21 23 22
Time period of study 1994Y2005 1989Y2008 1984Y2012
Inclusion of 91 era
For donor age ? + +
For diagnostic strategies
Toxoplasma serology j T +
CMV ? ? ++
AR j + +
CAV j j +
For therapeutic strategies
Toxoplasma prophylaxis j + ++
CMV prophylaxis ? ? ++
CAV (e.g., PCI) ? ? +
Induction
immunosuppression
? ? +
Maintenance
immunosuppression
j + +
Early use of statins + j +
?, no information available; j, only one modification during the study;
T, only one criterion with minor modifications; +, two modifications; ++,
more than two modifications.
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age limit of donors has gradually shifted to 65 years with a median donor
age of 46 years during the last 10 years.
Immunosuppression and Rejection
Over the years, several regimens of induction therapy have been used,
initially within sequential randomized trials: ALG (lymphoglobulin; Institut
Merieux, Lyon, France), OKT3 (Ortho Pharmaceutical, Raritan, NJ), and BT563
(daclizumab, Zenapax; Roche, Basel, Switzerland) (16Y18). Later on, ALG
(lymphoglobulin) was used, and during recent years, rabbit antithymocyte
globulin (ATG; Fresenius, Kabi, The Netherlands) was administered.
From 1984 to 1999, maintenance immunosuppression consisted of cy-
closporine and steroids complemented with azathioprine or mycophenolate
mofetil (MMF) when two or more rejection episodes had occurred. From
2000 onwards, the regimen consisted of a combination of tacrolimus, ste-
roids, and MMF. Rejection episodes were treated with pulsed high doses of
steroids or rabbit ATG (initially rabbit ATG; National Institute for Public
Health, Bilthoven, The Netherlands and later on with rabbit ATG (Genzyme
Polyclonals, Marcy-l’E´toile, France) in cases of steroid-resistant rejection.
From 1984 to 1990, grading of acute rejection was according to
Billinghams’ original criteria, from 1990 to 2005 according to the Interna-
tional Society for Heart and Lung Transplantation (ISHLT) working for-
mulation for the standardization of grading, and from 2005 onwards
according to the revised ISHLT working formulation (19Y22). Rejection was
treated when ‘‘moderate rejection’’ or more, ‘‘grade 3A’’ or more, or ‘‘grade 2R’’
or more were diagnosed, respectively.
T. gondii Serology
All recipients were evaluated for specific IgG and IgM antibodies against
T. gondii by enzyme immunoassays (EIAs). In addition, donors of whom
serum samples were available were evaluated. Initially, T. gondiiYspecific
antibodies were tested by a homemade EIA method as described before
(23). From 2000 onwards, a commercially available EIA method (Vidas
TOXO IgG and IgM; bioMerieux, Lyon, France) was used according to the
manufacturer’s instructions. When the EIA method resulted in equivocal
test results, the Toxoplasma serostatus was determined by examination of
follow-up sera and/or by Western blot analysis as described before (23).
Infection Prophylaxis
Prophylaxis against T. gondii was applied in Toxoplasma seronegative
recipients of the heart of a Toxoplasma seropositive donor (or of the heart of
a donor of whom the serostatus was not known) according to the knowl-
edge at the time and sequentially consisted of a 6-month course of
spiramycin (1985Y1988) or pyrimethamine (1989Y1994). From 1995 to July
2011, the combination of pyrimethamine and sulfadiazine was used. The
administration of pyrimethamine was always combined with folinic acid.
In the early phase of the program, CMV seronegative recipients of the
heart of a seropositive donor received passive immunization with anti-CMV
immunoglobulins (Cytotect; Biotest Pharma, Dreieich, Germany) during
the first 72 days after transplantation (24). Later on, oral valganciclovir was
prophylactically administered for 6 months (or longer in case of rejection
treatment) in these CMV mismatched patients.
Assessment of Cardiac Allograft Vasculopathy
Annual coronary arteriography was performed during the first 7 years of
the program (25). Later on, coronary angiography (CAG) was performed
per protocol after 1 year and repeated only after 4 years when no disease
other than wall irregularities was shown. From year 5, CAG was performed
when annual myocardial perfusion imaging showed perfusion defects or
when electrocardiogram changes or other clinical signs of coronary syn-
dromes occurred (26). The use of statins (pravastatin) per protocol early
after transplantation was introduced in 1996.
Definitions
The presence of cardiac allograft vasculopathy was defined positive when
at least ISHLT- CAV1 was diagnosed by CAG (27). Early cardiac death was
defined as death caused by primary graft failure. Late cardiac death was
defined as death caused by arrhythmia, conduction disorder, unwitnessed
sudden death, or heart failure with angiographically or by postmortem
examination-proven allograft vasculopathy.
Statistical Analysis
Categorical variables were compared by chi-square tests and continuous
variables by Student’s t test. Cumulative survival analyses were constructed
using the KaplanYMeier method. Among patient subgroups, the MantelY
Haenszel log-rank test was used to compare survival. The Cox proportional
hazards model was used to identify independent risk factors for mortality.
Preselected patient characteristics were all variables described in Table 3,
independent of the P values.
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